Skip to content

Long-term outcomes of interstitial cystitis/bladder pain syndrome (IC/BPS) after stepwise managements

Perioperative safety of bladder hydrodistension in IC/BPS patients on antithrombotic therapy

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100055015
Enrollment
Unknown
Registered
2021-12-30
Start date
2019-07-01
Completion date
Unknown
Last updated
2023-01-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Interstitial cystitis/bladder pain syndrome

Interventions

Antithrombotic gourp:History of antithrombotic drugs
Non-antithrombotic group:None

Sponsors

De-yi Luo
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Over 18 years old when signing an informed consent; 2. Previously diagnosed with IC/BPS for a duration of > 6 months; 3. OLeary-Sant Interstitial Cystitis Symptom and Problem Index scores over 18; 4. Undergoing hydrodistension during the hospitalization; 5. Patients with complete medical records.

Exclusion criteria

Exclusion criteria: 1. General conditions (1) Currently diagnosed with cancer, or have previous history of cancer within the preceding 5 years; (2) Currently diagnosed with severe heart, lung, liver, kidney, or blood disorders; (3) Pregnant women. 2. Urological symptoms (1) Have previous history of urinary infection (e.g., bacterial cystitis, bladder tuberculosis, urethritis, genital chlamydia infection, and genital herpes) within 12 weeks; (2) Currently diagnosed with any of following diseases, which had similar symptoms with IC/BPS. 1) Bladder diseases (carcinoma, overactive bladder, neurogenic bladder, bladder stone, radiation cystitis); 2) Urethral diseases (urethral diverticulum, urethral stricture, urethral stone); 3) Gynaecological diseases (endometriosis, uterine fibroids, vaginitis, menopausal syndrome, pelvic organ prolapse); 4) Others (neurogenic urinary frequency, polyuria). (3) Have previous history of augmentation cystoplasty or cystectomy; (4) Have previous history of chemical compound (such as cyclophosphamide) derived cystitis. 3. Treatment related (1) History of the following therapies within 24 weeks: hydrodistension, intravesical laser therapy, intravesical electrical coagulation, transurethral resection, pelvic reconstructive surgery, nerve stimulation for pain relief; (2) Received intravesical instillation of any drugs within 12 weeks.

Design outcomes

Primary

MeasureTime frame
Complications;

Countries

China

Contacts

Public ContactDe-yi Luo

West China Hospital, Sichuan University

luodeyi1985@163.com+86 18980606809

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026